Alexander Drilon, MD
Thoracic Medical Oncologist & Early Drug Development Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
About Me
- Chief, Early Drug Development Service
I am a medical oncologist who specializes in the treatment of lung cancer. I work with a team of experts including surgeons, radiation oncologists, pathologists, and nurses. Our goal is to provide the best possible care and support for patients and their families.
Read more
As a member of the Thoracic Oncology Service, my research is focused on developing new treatments for lung cancer. I have a particular interest in studying ways to target molecular changes in patients’ tumors with new medicines.
I also specialize in early-phase clinical trials and am a member of our Developmental Therapeutics group. Our aim is to bring new drugs to patients with all types of cancer, particularly those for whom standard treatments have been exhausted.
I speak English, Spanish, and Filipino.
A thoracic medical oncologist is a cancer doctor who specializes in thoracic (thor-A-sik) cancers. These are cancers that have to do with the chest, including lung, tracheal (windpipe), and thymic (thymus) cancers.
An early drug development specialist tests new drugs to treat cancer. They have special training in research studies, known as clinical trials.
My Specialties
- Lung Cancer
- Early-Phase Clinical Trials
Education
- MD, University of the Philippines
Residencies
- Internal Medicine - St. Luke's-Roosevelt Hospital Center
Fellowships
- Medical Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Drilon sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Drilon
- A Phase 1/2 Study of BBI-355 in People With Advanced Solid Tumors
- A Phase I Study of NVL-520 in People with Solid Tumors
- A Phase I Study of NVL-655 in People with Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
- A Phase I/II Study of REGN5093-M114 in People with Advanced Non-Small Cell Lung Cancer
Read more
- A Phase I/II Study of TPX-0005 in Patients with Advanced Solid Tumors
- A Phase II Study of Cabozantinib in Patients with Advanced Non-Small Cell Lung Cancer
- A Phase III Study of Selpercatinib after Surgery or Radiation Therapy for RET Fusion-Positive Lung Cancer
- Clinical Trials Co-Investigated by Dr. Drilon
- A Phase 1 Study of ABBV-400 in People With Advanced Solid Tumors
- A Phase 1 Study of KIN-2787 in People With Advanced Cancers
- A Phase 1 Study of LY4050784 in People With Advanced Solid Tumors
- A Phase 1/2 Study of BBI-825 in People With Advanced Solid Tumors
- A Phase 1/2 Study of Lorlatinib Plus Ramucirumab in People With Advanced Lung Cancer
- A Phase 1/2 Study of MRTX1133 in People With Solid Tumors That Have a KRAS G12D Gene Mutation
- A Phase 3 Study of Sotorasib in People With Non-Small Cell Lung Cancer
- A Phase I/II Study of MCLA-128 in People with Advanced Solid Tumors with NRG1 Gene Fusions
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Drilon’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Alexander Drilon discloses the following relationships and financial interests:
-
AnHeart Therapeutics Inc.
Professional Services and Activities -
Associazione Italiana Oncologia Toracica (AIOT)
Professional Services and Activities -
Boundless Bio, Inc.
Professional Services and Activities -
Bristol-Myers Squibb
Professional Services and Activities -
Didactika S.r.l.
Professional Services and Activities (Uncompensated) -
Doc Congress S.r.l.
Professional Services and Activities -
InnoCare Pharma Inc.
Professional Services and Activities -
La Paz University Hospital
Professional Services and Activities -
Loxo Oncology
Professional Services and Activities -
LUNGevity Foundation, Inc.
Professional Services and Activities (Uncompensated) -
MBrace Therapeutics, Inc.
Equity
-
Medscape
Professional Services and Activities -
MEDtalks Nederland BV
Professional Services and Activities -
Northwell Health
Professional Services and Activities -
PeerView Institute for Medical Education (PVI)
Professional Services and Activities -
Physicians' Education Resource
Professional Services and Activities -
PRIME Education LLC
Professional Services and Activities -
Projects In Knowledge
Professional Services and Activities -
Springer Nature Group
Professional Services and Activities -
Total CME
Professional Services and Activities -
Treeline Biosciences, Inc.
Equity; Professional Services and Activities -
Zymeworks Inc.
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].